Understand the MoA of PARP inhibitors and targeting DNA Damage Response (DDR)
Understand the MoA of PARP inhibitors and targeting DNA Damage Response (DDR)
Dr. Robert L. Coleman, Prof. Simon Boulton
A short video explaining the concept of DDR, the role of Homologous Recombination Repair (HRR) in DNA repair and the impact of BRCA1 and BRCA2 mutations. It explores PARP inhibitors as the proof of concept for targeting DDR, demonstrating how they work and their clinical benefit.
Dr. Robert L. Coleman
Gynaecologic Oncologist
US Oncology Research
United States (US)
Dr. Robert L. Coleman has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Simon Boulton
Senior Scientist
Francis Crick Institute
United Kingdom (UK)
Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Video | 5 min | Sep 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4